Journey Medical Corporation DERM Accutane — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Journey Medical Corporation in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Journey Medical Corporation's accutane — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Journey Medical Corporation's accutane — revenue?
- Journey Medical Corporation (DERM) reported accutane — revenue of $3.31M in Q1 2026.
- How has Journey Medical Corporation's accutane — revenue changed year-over-year?
- Journey Medical Corporation's accutane — revenue decreased by 9.3% year-over-year, from $3.66M to $3.31M.
- What is the long-term trend for Journey Medical Corporation's accutane — revenue?
- Over 2 years (2023 to 2025), Journey Medical Corporation's accutane — revenue has grown at a -20.1% compound annual growth rate (CAGR), from $20.17M to $12.88M.
- What does accutane — revenue mean?
- This represents the gross revenue generated from the sale of Accutane products to customers, excluding any sales-based taxes collected. It is a primary indicator of the product's market demand and commercial performance within the dermatology portfolio. Tracking this metric allows for the assessment of the product's lifecycle stage and its contribution to overall corporate revenue.